Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 2, 1996, Pages 275-282

  Nishikimi, Toshio ^a   Kawano, Yuhei ^a   Saito, Yoshihiko ^a   Matsuoka, Hiroaki ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Aortocaval fistula; Heart failure; Vasopressin; Vasopressin V1 antagonist; Vasopressin V2 antagonist

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; MOZAVAPTAN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; CONTROLLED STUDY; DIURESIS; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE PRESSURE; HEMODYNAMICS; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; VASODILATATION;

ANIMALS; BENZAZEPINES; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; ORGAN SIZE; PIPERIDINES; QUINOLONES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN;

EID: 0030048232     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199602000-00015     Document Type: Article

References (24)

1. Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 1968;32:745-59.
2. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Beri T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6.
3. Goldsmith SR, Francis GS, Cowley AW, Levine T, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1: 1385-90.
4. Pruszczynski W, Vahanian A, Ardaillou R, Acar J. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J Clin Endocrinol Metab 1984; 58:599-605.
5. Hofbauer KG, Mah SC, Vasopressin antagonist: present and future. Kidney Int 1987;32:S76-82.
6. Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonist. J Lab Clin Med 1989;114:617-32.
7. Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991;252:572-4.
8. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105:787-91.
9. Yamada Y, Yamamura Y, Chihara T, et al. OPC-21268, a vasopressin antagonist, produces hypotension in spontaneously hypertensive rats. Hypertension 1994;23:200-4.
10. Fujisawa G, Ishikawa S, Tsuboi Y, Okada K, Saito T. Therapeutic efficacy of the non-peptide ADH antagonist OPC- 31260 in SIADH rats. Kidney Int 1994;44:19-23.
11. Nishikimi T, Frohlich ED. Glomerular hemodynamics in aortocaval fistula rats: role of renin-angiotensin system. Am J Physiol 1993;264;R681-6.
12. Nishikimi T, Tani T, Ohmura T, et al. Angiotensin II type-1 receptor antagonist as well as angiotensin converting enzyme inhibitor attenuates the development of heart failure in aortocaval fistula rats. Jpn Circ J 1995;59:754-61.
13. Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineral-ocorticoid hypertension in the rat. Hypertension 1994; 23(part1):737-43.
14. Nishikimi T, Miura K, Minamino N, Takeuchi K, Takeda T. Role of endogenous atrial natriuretic peptide on systemic and renal hemodynamics in heart failure rats. Am J Physiol 1994;267:H182-6.
15. Nishikimi T, Yamagishi H, Takeuchi K, Takeda T. Angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rats. Cardiovasc Res 1995;29:856-61.
16. Miyata A, Kangawa K, Matsuo H. Molecular forms of atrial natriuretic peptides in rat tissues and plasma. J Hypertens 1986;4(suppl 2):S9-11.
17. Flaim SF, Minster WJ, Nells SH, Clark DP. Chronic arteriovenous shunt: evaluation of a model for heart failure in rat. Am J Physiol 1979;236:H698-704
18. Liu Z, Hilbelnk DR, Crockett WB, Gerdes AM. Regional change in hemodymamics and cardiac myocyte size in rats with aortocaval fistula: 1. Developing and established hypertrophy. Circ Res 1991;69:52-8.
19. Riegger GAJ, Liebau G, Bauer E, Kochsiek K. Vasopressin and renin in high output failure of rats: hemodynamic effects of elevated plasma hormone levels. J Cardiovasc Pharmacol 1985;7:1-5.
20. Wang Y, Franco R, Gavras I, Gavras H. Effect of chronic administration of a vasopressin antagonist with combined antidepressor and antidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med 1991;117:313-8.
21. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-65.
22. Nicod P, Waeber B, Bussien JP, et al. Acute hemodynamic effect of a vascular antagonist in patients with congestive heart failure. Am J Cardiol 1985;55:1043-7.
23. Arnolda L, Mcgrath B, Johnston CI. Systemic and regional effects of vasopressin and angiotensin in acute left ventricular failure. Am J Physiol 1991;260(Heart Circ Physiol 29):H499-506.
24. Arnolda L, McGrath BP, Cocks M, Johnston CI. Vasoconstrictor role for vasopressin in experimental heart failure in the rabbit. J Clin Invest 1986;78:674-9.